Azenta, Inc. ( (AZTA) ) has released its Q4 earnings. Here is a breakdown of the information Azenta, Inc. presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Azenta, Inc. is a leading provider of life sciences solutions, offering cold-chain sample management and multiomics services to pharmaceutical, biotech, academic, and healthcare institutions globally. The company is headquartered in Burlington, Massachusetts, with operations across North America, Europe, and Asia.
In its latest earnings report, Azenta, Inc. announced a 6% year-over-year revenue growth for the fourth quarter of fiscal 2025, with a 4% increase on an organic basis. The company also reported a 4% revenue growth for the full fiscal year, alongside significant improvements in its adjusted EBITDA margin.
Key financial highlights include a notable 11% increase in Multiomics revenue for the fourth quarter, driven by advancements in Next Generation Sequencing and Gene Synthesis. The Sample Management Solutions segment also saw a modest 2% revenue growth. Azenta’s adjusted EBITDA for the year rose by 44% to $66 million, reflecting a 310 basis point expansion in margin.
Looking ahead, Azenta anticipates organic revenue growth of 3% to 5% for fiscal 2026, with a further 300 basis point expansion in adjusted EBITDA margin. The company is poised to continue its focus on customer-centric strategies and operational efficiencies to drive future growth.